Given the increased attention by clinicians, researchers and the pharmaceutical industry to the management and treatment of dementia not only in the elderly but also in increasingly younger populations, the demands for effective evidence-based pharmaceutical control of dementia and quantitative assessment of outcomes have increased. Since some first steps in the early 1960's to the controversial landmark paper of Summers and colleagues, to the most recent trials, it is clear both that much progress has been made, and that much remains to be done. This book is written to take stock of what is now usefully known, and to speculate on directions for the future.


Short Contents

About the Author
Kenneth Rockwood MD MPA FRCPC is Professor, Division of Geriatric Medicine, Department of Medicine and Kathryn Allen Weldon Professor of Alzheimer Research, Dalhousie University, Halifax NS, Canada. Serge Gauthier MD FRCPC is Professor and Director of the Alzheimer's Disease Research Unit, The McGill Centre for Studies in Aging (Le Centre McGill D'Etudes sur le Vieillissement), Douglas Hospital, Montreal PQ, Canada.

Reviews

"...a thorough and thoughtful examination of a complex area....a milestone in describing the playing field upon which drug trials of Alzheimer's disease should be conducted. It is a testament to how all the measures used to diagnose Alzheimer's disease do not equally gauge the progression of the disease. Alzheimer's disease is not monolithic, but varies greatly from stage to stage. This book promotes new ways of approaching this aspect of the disease."
-Doody's Reviews

Book Information
ISBN 9781841843216
Author Kenneth Rockwood
Format Hardback
Page Count 312
Imprint CRC Press
Publisher Taylor & Francis Ltd
Weight(grams) 1043g